Indication

Prevention of respiratory distress syndrome in the newborn

Respiratory distress syndrome in the newborn is an acute pulmonary disorder that predominantly affects premature neonates due to developmental deficiency of endogenous pulmonary surfactant and structural lung immaturity. Read more about Prevention of respiratory distress syndrome in the newborn

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Prevention of respiratory distress syndrome in the newborn therapies.

Showing 1–2 of 2 drugs

Filter & compare in the drug finder →Opens the drug finder with Prevention of respiratory distress syndrome in the newborn preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Prevention of respiratory distress syndrome in the newborn.

Respiratory distress syndrome in the newborn is an acute pulmonary disorder that predominantly affects premature neonates due to developmental deficiency of endogenous pulmonary surfactant and structural lung immaturity.

This surfactant deficiency increases alveolar surface tension, leading to widespread microatelectasis, ventilation-perfusion mismatch, reduced lung compliance, and progressive hypoxemia.

Clinically, affected neonates manifest symptoms shortly after birth, characterized by tachypnea, intercostal retractions, nasal flaring, audible expiratory grunting, and cyanosis.

Prophylactic management strategies focus on accelerating pulmonary maturation antenatally or replacing surfactant immediately postpartum to avert atelectasis and subsequent respiratory failure.

Personalize your experience

Follow Prevention of respiratory distress syndrome in the newborn and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it